Peptide · Research Monograph · GLP-1 receptor agonist (incretin mimetic)

GLP-1 S

GLP-1 Receptor Studies

GLP-1 S is a selective GLP-1 receptor agonist peptide. Its sequence is about 94 percent identical to the endogenous GLP-1 hormone, with one change that resists enzymatic cleavage. Research has measured insulin release, appetite signalling and gastric emptying. A fatty acid chain lets it bind albumin, which extends its half-life.

Formula
C187H291N45O59
Mol. weight
4113.58 Da
Length
31 residues
CAS
910463-68-2
View product & pricing → Lot records & COAs

For laboratory research use only - not for human or animal use

GLP-1 S vial from the Eon Peptides research catalog
Fig. 1GLP-1 S · 20mg · catalog photograph
Available in the Eon catalog - GLP-1 S from $85.00 View certificate of analysisILS Laboratories · 99.69% purity · Lot GLP1S-101926-20

Molecular data

Molecular formulaC187H291N45O59
Molecular weight4113.58 Da
SequenceHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-gGlu-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Sequence length31 residues
CAS / identifier910463-68-2
Physical formLyophilized powder
Available sizes20mg

The sequence

GLP-1 S is published as a 31-residue sequence. It is set below in reading order, ten residues to a row, numbered from the N-terminus. 2 positions are not standard L-residues and are named beneath the grid.

Fig. 2Primary sequence of GLP-1 S as published in the catalogue specification, 31 residues, numbered from the N-terminus. A filled square marks a residue with no one-letter code.

As publishedHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-gGlu-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

Residues
31
Published as
Three-letter code
Termini
Not stated in the specification
Non-standard positions
2
  • Aib 2 2-aminoisobutyric acid
  • Lys 20 side chain AEEA-AEEA-gGlu-C18 diacid

How it works

  1. GLP-1R

    GLP-1 Receptor Agonism

    Selectively binds GLP-1 receptors. Published characterisation describes glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying in study models. Insulin response scales with glucose, a property examined relative to non-incretin secretagogues.

    • Glucose-dependent insulin secretion
    • Glucagon suppression
    • Delayed gastric emptying
  2. CNS

    Central GLP-1R Signalling

    Engages GLP-1 receptors in the hypothalamus and hindbrain, with hunger, satiety and energy intake as the measured endpoints.

    • Food intake measured
    • Satiety signalling measured
    • Lower caloric intake
  3. PK

    Extended Half-Life Design

    A C18 fatty-diacid chain confers reversible albumin binding and resistance to DPP-4 degradation, extending the plasma half-life to roughly 7 days in research models.

    • ~165-hour half-life
    • Albumin-binding modification
    • DPP-4 resistant

What the research shows

  1. Metabolic

    Metabolic Receptor Research

    GLP-1 receptor agonism is a principal focus of metabolic research, and GLP-1 S is a selective agonist used as a reference compound in that work.

  2. Endocrine

    Glycemic Pathway Research

    GLP-1 S is studied for glucose-dependent insulin secretion and glycemic endpoints in metabolic research.

  3. Cardiometabolic

    Cardiovascular Outcomes

    Cardiometabolic signalling is a further area of research interest for this receptor class, beyond glucose handling.

  4. Neuroscience

    Hypothalamic & Reward Circuitry

    GLP-1 receptor signaling in the hypothalamus and hindbrain modulates satiety and food-reward pathways, a focus of ongoing neuroscience research.

Specification

Compound ClassGLP-1 receptor agonist (incretin mimetic)
Research NameGLP-1 S
TargetGLP-1 receptor (GLP-1R)
FormLyophilized powder
Molecular Weight4,113.58 g/mol
Purity≥99% (HPLC verified)
TestingThird-party HPLC, Mass Spec, Endotoxin
Half-Life~165 hours (~7 days)
Storage-20°C for long-term stability
SolubilityWater-soluble
COAIncluded with every order

How it's tested

Every lot of GLP-1 S released to the catalog carries a third-party certificate of analysis. 4 documented lots are on file for this compound, with reported HPLC purity from 99.69% to 99.90% (mean 99.78%), issued by ILS Laboratories and Accurate Test Labs. 2 of 4 certificates record identity as confirmed.

Documented lots
4
Reported purity
99.69% to 99.90%
Mean purity
99.78%
Issuing labs
ILS Laboratories, Accurate Test Labs
100% 99% 98% 99.78% Lot UJ68ET · 2026-08-18 · 99.77%Lot G1-091126-10 · 2026-09-15 · 99.90%Lot GLP1S-101926-20 · 2026-10-19 · 99.69%Lot GLP1-S-101926-10 · 2026-10-19 · 99.77% 2026-08-18 2026-10-19
Fig. 3Reported HPLC purity of all 4 documented lots, plotted on the date each certificate was issued, 2026-08-18 to 2026-10-19. One point is one certificate; the points are not joined because the archive records lots, not a continuous measurement. Vertical window 98.00% to 100%, dashed rule is the mean at 99.78%.

All certificates in the COA library →

Frequently asked questions

What is GLP-1 S?

GLP-1 S is a long-acting and selective GLP-1 receptor agonist. It mimics the incretin hormone GLP-1; published characterisation describes glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and central appetite-pathway signalling.

How does it differ from GLP-2 TZ and GLP-3 RT?

GLP-1 S is a single-receptor (GLP-1) agonist. GLP-2 TZ is a dual GLP-1/GIP agonist, and GLP-3 RT is a triple GLP-1/GIP/glucagon agonist. The distinction is receptor coverage.

What is the molecular weight and purity?

GLP-1 S has a molecular weight of 4,113.58 g/mol. Every vial is supplied at ≥99% purity, verified by HPLC, with a Certificate of Analysis included.

How should it be stored?

Store lyophilized vials at -20°C for long-term stability, protected from light and moisture.

Is this product for human use?

No. GLP-1 S is sold strictly as a research compound for laboratory and in-vitro use only. It is not intended for human or animal consumption, diagnosis, or treatment.

Other entries in this volume that bear on GLP-1 S, with the reason each one is listed.

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.